MX2021014102A - Terapia de vacuna anti-abeta. - Google Patents

Terapia de vacuna anti-abeta.

Info

Publication number
MX2021014102A
MX2021014102A MX2021014102A MX2021014102A MX2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A
Authority
MX
Mexico
Prior art keywords
administered
mpla
amyloid
amount
vaccine therapy
Prior art date
Application number
MX2021014102A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Muhs
Andrea Pfeifer
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2021014102A publication Critical patent/MX2021014102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021014102A 2019-05-21 2020-05-20 Terapia de vacuna anti-abeta. MX2021014102A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19175810 2019-05-21
EP19185593 2019-07-10
EP20171549 2020-04-27
EP20172205 2020-04-29
PCT/EP2020/064172 WO2020234405A1 (en) 2019-05-21 2020-05-20 Anti-abeta vaccine therapy

Publications (1)

Publication Number Publication Date
MX2021014102A true MX2021014102A (es) 2022-02-11

Family

ID=70740677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014102A MX2021014102A (es) 2019-05-21 2020-05-20 Terapia de vacuna anti-abeta.

Country Status (15)

Country Link
US (1) US20220226447A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972633A1 (cg-RX-API-DMAC7.html)
JP (1) JP7701734B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220010552A (cg-RX-API-DMAC7.html)
CN (1) CN113853214A (cg-RX-API-DMAC7.html)
AU (1) AU2020277682A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023209A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138145A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003051A1 (cg-RX-API-DMAC7.html)
IL (1) IL288252B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014102A (cg-RX-API-DMAC7.html)
MY (1) MY210394A (cg-RX-API-DMAC7.html)
SG (1) SG11202112329RA (cg-RX-API-DMAC7.html)
TW (1) TW202110425A (cg-RX-API-DMAC7.html)
WO (1) WO2020234405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI916375B (zh) * 2020-06-25 2026-03-01 英商梅迪繆思有限公司 軸突損傷之預防
WO2024156912A1 (en) * 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy
WO2025109524A1 (en) * 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta

Also Published As

Publication number Publication date
IL288252A (en) 2022-01-01
JP2022533422A (ja) 2022-07-22
MY210394A (en) 2025-09-18
KR20220010552A (ko) 2022-01-25
CN113853214A (zh) 2021-12-28
CA3138145A1 (en) 2020-11-26
SG11202112329RA (en) 2021-12-30
JP7701734B2 (ja) 2025-07-02
IL288252B1 (en) 2026-06-01
TW202110425A (zh) 2021-03-16
US20220226447A1 (en) 2022-07-21
WO2020234405A1 (en) 2020-11-26
BR112021023209A2 (pt) 2022-01-18
EP3972633A1 (en) 2022-03-30
CL2021003051A1 (es) 2022-07-22
AU2020277682A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MY210394A (en) Anti-abeta vaccine therapy
Barr et al. ISCOMs (immunostimulating complexes): the first decade
NZ701881A (en) Vaccines for hsv-2
CA2181832A1 (en) Immunization by inoculation of dna transcription unit
AU2012257771C1 (en) Vaccine against Streptococcus pneumoniae
BR9509190A (pt) Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano
US20050002951A1 (en) Novel method of inducing antigen-specific t cells
MY206596A (en) Method of safe administration of phosphorylated tau peptide vaccine
PH12021552683A1 (en) Heterologous administration of tau vaccines
WO2005000348A2 (en) Vaccines inducing nkt-cell and toll-like-receptor activation
JP2017511327A5 (cg-RX-API-DMAC7.html)
JP2021521149A5 (cg-RX-API-DMAC7.html)
RU2018120009A (ru) Способ вакцинации против аутоантигена у пациента-человека
DK2491946T3 (en) Adjuvant for vaccines
JP2010514669A5 (cg-RX-API-DMAC7.html)
US20230285531A1 (en) Toll-like receptor 2 agonists and vaccines and uses thereof
AU2003212170A1 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
RU2010126154A (ru) Эпитопные пептиды stat3
WO2013171661A3 (en) Adjuvant formulations and methods
WO2017070735A1 (en) Liposomal vaccine
MX2025008675A (es) Terapia con vacuna anti-abeta
EA202193183A1 (ru) Терапия с помощью вакцины против бета-амилоида
WO2001078774A3 (en) Recombinant intracellular pathogen vaccines and methods for use
FR2248025A2 (en) Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant
FR2324311A1 (fr) Adjuvants immunologiques solubles dans l'eau, notamment pour vaccins, obtenus a partir de mycobacteries et autres micro-organismes